Valeant Pharmaceuticals International Inc (VRX.TO)(VRX.N) said on Thursday that quarterly profit rose 66 percent on strength in Europe, Latin America, Canada and Australia. The Canadian company, which said it faced headwinds in the U.S. market, raised its earnings forecast for the year by 5 cents a share. Last month, unconfirmed media reports stated Valeant had approached Swedish specialty drug maker Meda AB (MEDAa.ST) about a possible acquisition. Valeant, which is one of the most acquisitive companies in healthcare, dropped a $5.7 billion bid for U.S. drugmaker Cephalon Inc (CEPH.O) in May. Its chief executive officer, Michael Pearson, told Reuters last month it was still on the lookout for big targets.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $52.26. In the past year, the shares have traded as low as $21.92 and as high as $57.24. On average, 2281950 shares of VRX exchange hands on a given day and today's volume is recorded at 200.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $52.26. In the past year, the shares have traded as low as $21.92 and as high as $57.24. On average, 2281950 shares of VRX exchange hands on a given day and today's volume is recorded at 200.
Cephalon, Inc. is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Shares of CEPH remained unchanged at $79.78. In the past year, the shares have traded as low as $54.15 and as high as $81.11. On average, 2097030 shares of CEPH exchange hands on a given day and today's volume is recorded at 1000.
Source
